Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

IMMIX BIOPHARMA, INC. +0.49% Pre

IMMIX BIOPHARMA, INC.

IMMX

2.05

2.05

+0.49%

0.00% Pre

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:

  • 10 years of market exclusivity once authorized in the EU
  • Access to the EU centralized authorization procedure
    • Reduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via